{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:32Z","timestamp":1793316332215,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.heliyon.2023.e13725","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T17:15:17Z","timestamp":1676394917000},"page":"e13725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation and management of acute high-grade immunotherapy-related neurotoxicity"],"prefix":"10.1016","volume":"9","author":[{"given":"Marcelo","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-6755","authenticated-orcid":false,"given":"Adriana H.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Alhajji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Viets-Upchurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8271-0054","authenticated-orcid":false,"given":"Patricia","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2037-3085","authenticated-orcid":false,"given":"Demis N.","family":"Lipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Al-breiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5256","key":"10.1016\/j.heliyon.2023.e13725_bib1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41587-022-01331-0","article-title":"FDA approves anti-LAG3 checkpoint","volume":"40","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e13725_bib7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e13725_bib9","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7528","key":"10.1016\/j.heliyon.2023.e13725_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"22","key":"10.1016\/j.heliyon.2023.e13725_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e13725_bib14","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.euf.2021.03.001","article-title":"Impact of clinicopathological features on survival in patients treated with first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors for renal cell carcinoma: a meta-analysis of randomized clinical trials","volume":"8","author":"Rizzo","year":"2022","journal-title":"Eur. Urol. Focus"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13725_bib16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3390\/cells9092051","article-title":"Is there a role for immunotherapy in prostate cancer?","volume":"9","author":"Rizzo","year":"2020","journal-title":"Cells"},{"issue":"36","key":"10.1016\/j.heliyon.2023.e13725_bib17","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib18","series-title":"Comprehensive cancer Network guidelines in oncology. Management of immunotherapy-related toxicities. Version 1. 2022 february 28","author":"National","year":"2022"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib19","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.anai.2021.03.003","article-title":"Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy","volume":"126","author":"Goleva","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s43018-021-00276-8","article-title":"LAG-3 and PD-1 blockade raises the bar for melanoma","volume":"2","author":"Robert","year":"2021","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J. Emerg. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14737140.2019.1562342","article-title":"Management of immune-related adverse events resulting from immune checkpoint blockade","volume":"19","author":"Baroudjian","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.heliyon.2023.e13725_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.779915","article-title":"Advances in knowledge and management of immune-related adverse events in cancer immunotherapy","volume":"13","author":"Olsen","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","article-title":"Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid","volume":"164","author":"Pluim","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.heliyon.2023.e13725_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fnmol.2019.00282","article-title":"Immune checkpoint blockade - how does it work in brain metastases?","volume":"12","author":"Lorger","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjc.2017.142","article-title":"Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases","volume":"116","author":"Parakh","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bju.14461","article-title":"Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme","volume":"123","author":"De Giorgi","year":"2019","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41582-021-00617-2","article-title":"Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?","volume":"18","author":"Schagen","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s13311-022-01184-0","article-title":"Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors","volume":"19","author":"Duong","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.heliyon.2023.e13725_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420932797","article-title":"Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors","volume":"13","author":"Vogrig","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13725_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/practneurol-2021-003073","article-title":"Paraneoplastic neurological syndromes: a practical approach to diagnosis and management","volume":"22","author":"Binks","year":"2022","journal-title":"Practical Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib37","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib39","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database","volume":"145","author":"Sato","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib43","doi-asserted-by":"crossref","first-page":"e227722","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"Mohn","year":"2019","journal-title":"J. Clin. Med."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e13725_bib45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2023.e13725_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120089","article-title":"CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review","volume":"432","author":"Khan","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib48","series-title":"Common Terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib49","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother. Adv."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib50","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ajco.13375","article-title":"Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature","volume":"16","author":"Fan","year":"2020","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib55","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib56","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s10072-022-05920-4","article-title":"Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice","volume":"43","author":"Villagran-Garcia","year":"2022","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas","year":"2018","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib58","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","article-title":"Neurological sequelae of cancer immunotherapies and targeted therapies","volume":"17","author":"Wick","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib59","article-title":"Guillain-barre syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint inhibitor-related Guillain-Barre syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","journal-title":"J. Immunother."},{"key":"10.1016\/j.heliyon.2023.e13725_bib61","article-title":"Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: a case report and review of the literature","volume":"36","author":"Brzezinska","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","article-title":"Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report","volume":"6","author":"Appelbaum","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib63","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s40425-019-0748-0","article-title":"Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma","volume":"7","author":"Gao","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.heliyon.2023.e13725_bib65","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/imt-2020-0350","article-title":"Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer","volume":"13","author":"Trontzas","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.heliyon.2023.e13725_bib66","article-title":"Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy","volume":"2020","author":"Mohn","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.heliyon.2023.e13725_bib68","first-page":"e000540","article-title":"How we treat neurological toxicity from immune checkpoint inhibitors","volume":"4","author":"Spain","year":"2019","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10072-019-04163-0","article-title":"Practical approach to respiratory emergencies in neurological diseases","volume":"41","author":"Racca","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.heliyon.2023.e13725_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am. J. Emerg. Med."},{"issue":"50","key":"10.1016\/j.heliyon.2023.e13725_bib71","doi-asserted-by":"crossref","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/CMR.0000000000000598","article-title":"Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma","volume":"29","author":"Mohn","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.heliyon.2023.e13725_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.655283","article-title":"Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab","volume":"12","author":"Charabi","year":"2021","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13725_bib74","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-reactive protein as an early marker of immune-related adverse events","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib75","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib76","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib77","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","article-title":"Inflammatory markers in autoimmunity induced by checkpoint inhibitors","volume":"147","author":"Husain","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib78","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CMR.0000000000000748","article-title":"C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting","volume":"31","author":"Lauwyck","year":"2021","journal-title":"Melanoma Res."},{"key":"10.1016\/j.heliyon.2023.e13725_bib79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e13725_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117424","article-title":"Neurological complications of immune checkpoint inhibitor cancer immunotherapy","volume":"424","author":"Zivelonghi","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e13725_bib81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.0000000000011812","article-title":"The role of immune checkpoint therapy in propagating neurologic immune-related adverse events: inducing or \"unmasking\" autoimmunity?","volume":"96","author":"Gardin","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2023.e13725_bib82","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin","year":"2021","journal-title":"Ther. Adv. Drug Saf."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"suppl_4","key":"10.1016\/j.heliyon.2023.e13725_bib84","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib85","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib86","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp-2020-323212","article-title":"Encephalitis as an immune-related adverse event","volume":"91","author":"Suzuki","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib87","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","article-title":"Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies","volume":"71","author":"Seki","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib88","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11060-022-03997-7","article-title":"Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review","volume":"157","author":"Nannini","year":"2022","journal-title":"J. Neuro Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.29245\/2572.942X\/2016\/4.1040","article-title":"Central nervous system toxicities of anti-cancer immune checkpoint blockade","volume":"1","author":"Blackmon","year":"2016","journal-title":"J. Neurol. Neuromed."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib90","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00381-005-1176-7","article-title":"The role of posterior fossa decompression in acute cerebellitis","volume":"21","author":"de Ribaupierre","year":"2005","journal-title":"Childs Nerv. Syst."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14802\/jmd.20040","article-title":"Immune-Mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms","volume":"14","author":"Mitoma","year":"2021","journal-title":"J. Mov. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1212\/WNL.0000000000005781","article-title":"Autoimmune pancerebellitis associated with pembrolizumab therapy","volume":"91","author":"Vitt","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2017.12.001","article-title":"Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy","volume":"2","author":"Zurko","year":"2018","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib94","doi-asserted-by":"crossref","first-page":"e231520","DOI":"10.1136\/bcr-2019-231520","article-title":"Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor","volume":"12","author":"Saikawa","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12755","article-title":"CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer","volume":"48","author":"Hardwick","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib96","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3174\/ajnr.A0928","article-title":"Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features","volume":"29","author":"Bartynski","year":"2008","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib97","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11912-008-0013-z","article-title":"Reversible posterior leukoencephalopathy syndrome in cancer","volume":"10","author":"Vaughn","year":"2008","journal-title":"Curr. Oncol. Rep."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e13725_bib98","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib99","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib100","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jemermed.2021.09.005","article-title":"Posterior reversible encephalopathy syndrome: a narrative review for emergency clinicians","volume":"61","author":"Mergen","year":"2021","journal-title":"J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib101","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11912-008-0010-2","article-title":"Seizures and epilepsy in cancer: etiologies, evaluation, and management","volume":"10","author":"Grewal","year":"2008","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib103","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","article-title":"Posterior reversible encephalopathy syndrome in patients with cancer","volume":"20","author":"Singer","year":"2015","journal-title":"Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib104","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","article-title":"Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma","volume":"30","author":"Maur","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1212\/CPJ.0000000000000362","article-title":"Nivolumab-induced posterior reversible encephalopathy syndrome","volume":"7","author":"Hussein","year":"2017","journal-title":"Neurol. Clin. Pract."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib106","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1078155215620922","article-title":"Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma","volume":"23","author":"LaPorte","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib107","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib108","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ccr3.2122","article-title":"Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer","volume":"7","author":"Kim","year":"2019","journal-title":"Clin. Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/apjon.apjon_49_20","article-title":"Identification and management of posterior reversible encephalopathy syndrome in a patient enrolled in an immunotherapy combination phase I clinical trial: a case study","volume":"8","author":"Barber","year":"2021","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2023.e13725_bib110","article-title":"Posterior reversible encephalopathy syndrome (PRES) and drug-induced hypersensitivity syndrome (DIHS) following immunotherapy and BRAF\/MEK inhibition with continued response in metastatic melanoma","volume":"2021","author":"Sabile","year":"2021","journal-title":"Case Rep. Oncol. Med."},{"key":"10.1016\/j.heliyon.2023.e13725_bib111","article-title":"Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer","volume":"31","author":"Foulser","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib112","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib113","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib114","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40120-022-00363-7","article-title":"A narrative review on axonal neuroprotection in multiple sclerosis","volume":"11","author":"Collongues","year":"2022","journal-title":"Neurol. Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13725_bib115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib116","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition","volume":"21","author":"Pan","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heliyon.2023.e13725_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarran","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib119","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00228-020-02959-0","article-title":"Durvalumab and multiple sclerosis: a causal link or simple unmasking?","volume":"76","author":"Caputo","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib120","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib121","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib122","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/cmi.2017.142","article-title":"Guillain-Barre syndrome, transverse myelitis and infectious diseases","volume":"15","author":"Rodriguez","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/CON.0000000000000900","article-title":"Myelitis and other autoimmune Myelopathies","volume":"27","author":"Lopez Chiriboga","year":"2021","journal-title":"Continuum"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib124","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib126","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib127","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000773","article-title":"Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors","volume":"7","author":"Nowosielski","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2023.e13725_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalSci"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12883-022-02576-7","article-title":"Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report","volume":"22","author":"Moodie","year":"2022","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib131","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-Interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib132","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib133","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.heliyon.2023.e13725_bib134","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events","volume":"46","author":"Nasralla","year":"2020","journal-title":"Multi Scler. Relat. Disord."},{"key":"10.1016\/j.heliyon.2023.e13725_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.806501","article-title":"Case report: neuromyelitis optica after treatment of uveal melanoma with nivolumab and ipilimumab","volume":"12","author":"Khimani","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib136","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s00415-021-10913-y","article-title":"Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab","volume":"269","author":"Weiss","year":"2022","journal-title":"J. Neurol."},{"issue":"9 Suppl 2","key":"10.1016\/j.heliyon.2023.e13725_bib137","first-page":"S38","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2004-817906","article-title":"Acute haemorrhagic encephalomyelitis (AHEM): MRI findings","volume":"35","author":"Mader","year":"2004","journal-title":"Neuropediatrics"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e13725_bib139","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung","volume":"19","author":"Matsuoka","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2023.e13725_bib140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-associated acute demyelinating encephalitis: a case report and literature review","volume":"17","author":"Zafar","year":"2019","journal-title":"Clin. Med. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib141","doi-asserted-by":"crossref","first-page":"e002732","DOI":"10.1136\/jitc-2021-002732","article-title":"Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis","volume":"9","author":"Bjursten","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib142","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain-Barre syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"2021","journal-title":"J. Neurol."},{"issue":"10280","key":"10.1016\/j.heliyon.2023.e13725_bib143","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barre Syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"McNeill","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib145","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1016\/j.clgc.2019.07.020","article-title":"Fatal acute motor axonal neuropathy induced by nivolumab: a case report and literature review","volume":"17","author":"Yildirim","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib146","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","article-title":"Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"268","author":"Okada","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib147","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expet Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib148","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e13725_bib149","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib150","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management","volume":"90","author":"Watson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.heliyon.2023.e13725_bib151","series-title":"StatPearls","article-title":"Neuropathy","author":"Hammi","year":"2022"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e13725_bib152","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib153","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib154","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajco.12838","article-title":"Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis","volume":"14","author":"Man","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib155","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin. Neurophysiol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib156","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CJI.0000000000000313","article-title":"Brief communication: immune checkpoint inhibitor-induced diaphragmatic dysfunction: a case series","volume":"43","author":"Archibald","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.heliyon.2023.e13725_bib157","article-title":"Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy","volume":"34","author":"Srinivasan","year":"2021","journal-title":"Respir. Med. Case Rep."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e13725_bib158","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib159","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.heliyon.2023.e13725_bib161","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e13725_bib162","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.heliyon.2023.e13725_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.858628","article-title":"Association between clinical factors and result of immune checkpoint inhibitor related myasthenia gravis: a single center experience and systematic review","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e13725_bib164","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2023.e13725_bib165","series-title":"StatPearls","article-title":"Myasthenia gravis","author":"Beloor Suresh","year":"2022"},{"issue":"14","key":"10.1016\/j.heliyon.2023.e13725_bib166","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e13725_bib167","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/acn3.654","article-title":"Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia","volume":"5","author":"Takamatsu","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e13725_bib168","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul. Disord."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e13725_bib169","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13256-022-03286-x","article-title":"Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report","volume":"16","author":"Saishu","year":"2022","journal-title":"J. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e13725_bib171","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e13725_bib172","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e13725_bib173","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","article-title":"Myasthenia gravis induced by immune checkpoint inhibitors","volume":"42","author":"Becquart","year":"2019","journal-title":"J. Immunother."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023009325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023009325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:00:06Z","timestamp":1776214806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023009325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2405844023009325"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13725","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and management of acute high-grade immunotherapy-related neurotoxicity","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e13725"}}